Stoke Therapeutics filed for its IPO that could be worth up to $86 million. The Bedford, MA-based company is developing therapies to treat severe genetic diseases by, “precisely protein... read more
Stoke Therapeutics filed for its IPO that could be worth up to $86 million. The Bedford, MA-based company is developing therapies to treat severe genetic diseases by, “precisely protein... read more
Fountain Healthcare Partners (“Fountain”) announced on 5/23/19 the initial closing of its third fund, Fountain Healthcare Partners Fund III, L.P. (“Fund III”) with €118 million of committed... read more
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced on 5/22/19 the pricing of its underwritten public offering of 7,000,000 shares of its... read more
Sofinnova Partners, a European venture capital firm specializing in Life Sciences, announced today the launch of MD Start III, which closed above its original target of €40 million. With this new... read more
Guardant Health Filed for a public offering of up to 5,175,000 shares of common stock. At current prices this would raise $405 million+. Guardant trades on NASDAQ under the symbol, “GH.”
... read more